These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 10383920)

  • 21. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
    Ma B; Prueksaritanont T; Lin JH
    Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
    Miyazawa M; Shindo M; Shimada T
    Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
    Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
    Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
    Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
    Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions.
    Vickers AE; Sinclair JR; Zollinger M; Heitz F; Glänzel U; Johanson L; Fischer V
    Drug Metab Dispos; 1999 Sep; 27(9):1029-38. PubMed ID: 10460803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes.
    Echizen H; Kawasaki H; Chiba K; Tani M; Ishizaki T
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1425-31. PubMed ID: 8450476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate.
    Suzuki A; Iida I; Tanaka F; Akimoto M; Fukushima K; Tani M; Ishizaki T; Chiba K
    Drug Metab Dispos; 1999 Nov; 27(11):1254-9. PubMed ID: 10534309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents.
    Iatsimirskaia E; Tulebaev S; Storozhuk E; Utkin I; Smith D; Gerber N; Koudriakova T
    Clin Pharmacol Ther; 1997 May; 61(5):554-62. PubMed ID: 9164417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decrease in a constitutive form of cytochrome P-450 by macrolide antibiotics.
    Miura T; Iwasaki M; Komori M; Ohi H; Kitada M; Mitsui H; Kamataki T
    J Antimicrob Chemother; 1989 Oct; 24(4):551-9. PubMed ID: 2515189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of nifedipine metabolism in dogs by erythromycin: difference between the gut wall and the liver.
    Tsuruta S; Nakamura K; Arimori K; Nakano M
    J Pharm Pharmacol; 1997 Dec; 49(12):1205-10. PubMed ID: 9466344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic drug interactions of macrolides.
    Periti P; Mazzei T; Mini E; Novelli A
    Clin Pharmacokinet; 1992 Aug; 23(2):106-31. PubMed ID: 1511528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Rokitamycin in odontostomatology. Controlled study of doses].
    Fornaseri C; Carbone V; Giangrandi D; Giordano M; Mortellaro C
    Minerva Stomatol; 1997 Dec; 46(12):693-9. PubMed ID: 9567620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acanthamoeba castellanii.
    Mattana A; Biancu G; Alberti L; Accardo A; Delogu G; Fiori PL; Cappuccinelli P
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4520-7. PubMed ID: 15561820
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Minegishi G; Kazuki Y; Nitta SI; Miyajima A; Akita H; Kobayashi K
    Xenobiotica; 2021 Jul; 51(7):764-770. PubMed ID: 34013847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of rokitamycin, a new 16-membered macrolide, on serum theophylline.
    Cazzola M; Matera MG; Paternò E; Scaglione F; Santangelo G; Rossi F
    J Chemother; 1991 Aug; 3(4):240-4. PubMed ID: 1779258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivation of the macrolide antibiotics erythromycin, midecamycin, and rokitamycin by pathogenic Nocardia species.
    Yazawa K; Mikami Y; Sakamoto T; Ueno Y; Morisaki N; Iwasaki S; Furihata K
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2197-9. PubMed ID: 7811046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serious erythromycin interactions caused by inhibition of drug metabolism in the liver.
    Wynn RL
    Gen Dent; 1996; 44(6):486-8, 490. PubMed ID: 9515389
    [No Abstract]   [Full Text] [Related]  

  • 39. [Rokitamycin tolerance in patients with adverse reactions to chemotherapeutic agents].
    Cenci L; Nettis E; Berteramo R; Ferrannini A
    Clin Ter; 1996 Dec; 147(12):621-6. PubMed ID: 9296921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of rokitamycin on bilirubin-albumin binding: a study in vitro.
    Yamamura H; Ohsugi M; Kobayashi Y; Sasaki M
    J Toxicol Sci; 1993 Aug; 18(3):203-6. PubMed ID: 8246313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.